ReviewInternational journal of molecular sciences2016
Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 112 citations in OpenAlex.
- Trial
- Increased Risk of Psoriasis in Young Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.Annals of dermatology · 2026Article
- Prevalence of Metabolic-Dysfunction-Associated Steatotic Liver Disease in Patients with Psoriasis and Psoriatic Arthritis.Diagnostics (Basel, Switzerland) · 2026Article
- Prevalence of Steatotic Liver Disease with Fibrosis and Diagnostic Screening Tools in Patients with Psoriasis.Acta dermato-venereologica · 2026Article
- Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities.Inflammopharmacology · 2026Review
- Article
- Microarray Data Analysis of Gene Crosstalk Between Psoriasis and Non-Alcoholic Fatty Liver Disease.Clinical, cosmetic and investigational dermatology · 2026Article
- Non-alcoholic steatohepatitis incidence in patients with psoriasis vulgaris.Wiener medizinische Wochenschrift (1946) · 2025Observational
- Epidemiological Profile of Psoriasis and Linked Comorbidities in Chinese Population at Shenzhen: A Cross-Sectional Study.Health science reports · 2025Article
- Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?World journal of hepatology · 2025Review
- The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- [Metabolic-associated fatty liver disease (MAFLD): a multisystemic disease beyond the liver].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Correlation between cardiometabolic index and psoriasis: a cross-sectional analysis using NHANES data.Frontiers in physiology · 2025Article
- MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review.Therapeutic advances in gastroenterology · 2025Review
- Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study.Journal of clinical medicine · 2024Article
- Managing the Patient with Psoriasis and Metabolic Comorbidities.American journal of clinical dermatology · 2024Review
- Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet-A Comprehensive Review.International journal of molecular sciences · 2024Review
- Vibration-controlled transient elastography for non-invasive screening of liver fibrosis and steatosis in Turkish patients with psoriasis: A cross-sectional study.Hepatology forum · 2024Article
- A Bibliometric Analysis of Global Research Trends in Psoriasis and Metabolic Syndrome.Clinical, cosmetic and investigational dermatology · 2024Article
- Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case-control study and serological comparison.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 10 years, it has become increasingly evident that nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that affects multiple extra-hepatic organ systems and interacts with the regulation of several metabolic and immunological pathways. In this review we discuss the rapidly expanding body of clinical and epidemiological evidence supporting a strong association between NAFLD and chronic plaque psoriasis. We also briefly discuss the possible biological mechanisms underlying this association, and discuss treatment options for psoriasis that may influence NAFLD development and progression. Recent observational studies have shown that the prevalence of NAFLD (as diagnosed either by imaging or by histology) is remarkably higher in psoriatic patients (occurring in up to 50% of these patients) than in matched control subjects. Notably, psoriasis is associated with NAFLD even after adjusting for metabolic syndrome traits and other potential confounding factors. Some studies have also suggested that psoriatic patients are more likely to have the more advanced forms of NAFLD than non-psoriatic controls, and that psoriatic patients with NAFLD have more severe psoriasis than those without NAFLD. In conclusion, the published evidence argues for more careful evaluation and surveillance of NAFLD among patients with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.